

## **Dyadic to Present at Industry and Investor Events in October**

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October:

Enzyme Engineering XXVII, October 1-6, 2023

Park Royal Hotel, Singapore

Dr. Ronen Tchelet, Chief Scientific Officer

*“The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics”*

Wednesday, October 4, 2023, 11:00 AM – 11:30 AM

LD Mirco Main Event XVI, October 3-5, 2023

Luxe Sunset Blvd Hotel, Los Angeles, CA

Mark Emalfarb, President, and Chief Executive Officer

*“Next Generation Proteins for World Health, Nutrition and Wellness”*

Wednesday, October 4, 2023, 8:00 AM – 8:25 AM

World Vaccine Congress Europe, October 16-19, 2023

Fira de Barcelona Montjuic, Barcelona, Spain

Mark Emalfarb, President, and Chief Executive Officer

*“Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines”*

Wednesday, October 18, 2023, 11:45 AM – 12:00 PM

If you would like to connect with Dyadic’s management at any of the events, you may request a one-on-one meeting at [jlavalley@dyadic.com](mailto:jlavalley@dyadic.com).

### **About Dyadic International, Inc.**

Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness.

Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus *Thermothelomyces heterothallica* (formerly *Myceliophthora*

*thermophila*). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.

To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit <http://www.dyadic.com>.

### **Safe Harbor Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at [www.dyadic.com](http://www.dyadic.com).

### **Contact:**

Dyadic International, Inc.  
Ping W. Rawson  
Chief Financial Officer  
Phone: (561) 743-8333

Email: [ir@dyadic.com](mailto:ir@dyadic.com)

